NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Structured Abstract
Background:
Depression is relatively common in primary care patients but is not always identified by primary care providers.
Purpose:
To systematically review evidence to update the benefits and harms of screening for depression in general and older adults, and to also consider evidence for benefits and harms in pregnant and postpartum women, which was not previously reviewed, to aid the U.S. Preventive Services Task Force in updating its recommendation on this topic.
Methods:
We searched MEDLINE, PubMed, PsycINFO, and the Cochrane Collaboration Registry of Controlled Trials through January 20, 2015, to identify relevant literature published after searches of previous reviews of depression screening in general and older adults (new searches beginning January 1, 2009) and pregnant and postpartum women (new searches beginning January 1, 2012). We also examined references of other existing systematic reviews; searched Web sites of government agencies, professional organizations, and other organizations for grey literature; and monitored health news Web sites and journal tables of contents to identify potentially eligible trials. Two investigators independently reviewed identified abstracts and full-text articles against a set of a priori inclusion and quality criteria. One investigator abstracted data into an evidence table and a second investigator checked these data. We conducted random- effects meta-analyses to estimate the benefit of cognitive behavioral therapy (CBT) in pregnant and postpartum women.
Results:
We included 71 studies reported in 91 publications. Nine trials addressed screening in general (five trials; n=2,924) and older (four trials; n=890) adults. The remaining targeted pregnant and postpartum women, addressing the benefits of screening (six trials; n=11,869); harms of screening (one trial; n=462); benefits of treatment (18 trials; n=1,638); harms of treatment with second-generation antidepressants (one systematic review, including 15 studies in pregnant women with depression and 109 studies in general pregnant populations, one trial [n=87], and 12 observational studies [n=4,759,735]); and diagnostic accuracy of selected screening instruments (26 studies; n=6,175). Most studies of antidepressant harms were limited to pregnant women, but evidence for other questions primarily focused on postpartum women.
Trials in postpartum women showed 28 to 59 percent reductions in the risk of depression at 3- to 5-month followup after participating in programs involving depression screening, with or without additional treatment components, compared to usual care. For identifying major depressive disorder using a cutoff of 13 on the English-language Edinburgh Postnatal Depression Scale, sensitivity ranged from 0.67 (95% CI, 0.18 to 0.96) to 1.00 (95% CI, 0.67 to 1.00) and specificity ranged from 0.87 (95% CI, 0.79 to 0.93) to 0.99 (95% CI, 0.97 to 1.00). Pooled results for the benefit of CBT in pregnant and postpartum women with screen-detected depression showed a 34 percent increase in the likelihood of remission with CBT (pooled RR, 1.34 [95% CI, 1.19 to 1.50]; k=10; I2=7.9%) compared to waitlist or usual care. Observational evidence showed that second-generation antidepressant use during pregnancy may be associated with small increases in the risk of preeclampsia, postpartum hemorrhage, miscarriage, perinatal death, preterm birth, being small for gestational age, infant seizures, serotonin withdrawal syndrome, respiratory distress, pulmonary hypertension, major malformations, and cardiac malformations.
Screening programs generally increased the likelihood of remission and treatment response in general adult populations (k=5) experiencing depressive symptoms, but typically included additional treatment supports. None of the trials limited to older adults (k=4) showed a benefit of the screening program, and one showed a statistically nonsignificant adverse effect on depression remission.
Conclusions:
Although direct evidence of the isolated health benefit of depression screening in primary care is weak, the totality of the evidence supports the benefits of screening in pregnant and postpartum and general adult populations, particularly in the presence of additional treatment supports such as treatment protocols, care management, and availability of specially trained depression care providers. Evidence is least supportive of screening in older adults, where direct evidence is most limited.
Contents
- 1. Introduction
- Condition Definition
- Prevalence and Risk Factors for Depression
- Burden of Depression
- Etiology and Natural History
- Current Clinical Practice
- Rationale for Screening for Depression
- Screening Instruments
- Interventions to Treat Depression
- Current U.S. Initiatives and Recommendations of Other Organizations
- Previous USPSTF Recommendation
- 2. Methods
- 3. Results
- 4. Discussion
- References
- Appendix A FDA Antidepressant Drug Labels for Pregnant and Postpartum Women
- Appendix B Detailed Methods
- Appendix C Excluded Studies
- Appendix D Evidence Tables
- Appendix E Benefits of Depression Treatment in General and Older Adults With Screen-Detected Depression
- Appendix F Screening Accuracy of the PHQ and GDS
- Appendix G Ongoing Studies
Acknowledgements: The authors acknowledge the following individuals for their contributions to this project: Karen Lee, MD, MPH, at AHRQ; current and former members of the U.S. Preventive Services Task Force who contributed to topic deliberations; Bradley N. Gaynes, MD, MPH, and Gregory E. Simon, MD, MPH, for expert input on the review scope and draft report; Barbara Yawn, MD, Marian McDonagh, PharmD, and Ramin Mojtabai, MD, PhD, MPH, for providing expert review of the draft report; the Centers for Disease Control and Prevention, the National Institute of Mental Health, the U.S. Air Force, and the Substance Abuse and Mental Health Services Administration for providing federal partner review of the draft report; and Smyth Lai, MLS, and Kevin Lutz, MFA, at the Kaiser Permanente Center for Health Research.
Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services1 . Contract No. HHSA-290-2012-00151-I, Task Order No. 2. Prepared by: Kaiser Permanente Research Affiliates Evidence-based Practice Center2
Suggested citation:
O'Connor E, Rossom RC, Henninger M, Groom HC, Burda BU, Henderson JT, Bigler KD, Whitlock EP. Screening for Depression in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 128. AHRQ Publication No. 14-05208-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
This report is based on research conducted by the Kaiser Permanente Research Affiliates Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-290-2012-00151-I, Task Order No. 2). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).
The final report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
- 1
5600 Fishers Lane, Rockville, MD 20857; www
.ahrq.gov - 2
Kaiser Permanente Center for Health Research, Portland, OR
- Review Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2014]Review Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceHenderson JT, Whitlock EP, O'Conner E, Senger CA, Thompson JH, Rowland MG. 2014 Apr
- Review Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force.[JAMA. 2016]Review Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force.O'Connor E, Rossom RC, Henninger M, Groom HC, Burda BU. JAMA. 2016 Jan 26; 315(4):388-406.
- Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force[ 2020]Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task ForcePatnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG, Lin JS. 2020 Feb
- Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force[ 2013]Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task ForceLin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E. 2013 Nov
- Review Screening for Chronic Obstructive Pulmonary Disease: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Chronic Obstructive Pulmonary Disease: A Systematic Evidence Review for the U.S. Preventive Services Task ForceGuirguis-Blake JM, Senger CA, Webber EM, Mularski R, Whitlock EP. 2016 Apr
- Screening for Depression in AdultsScreening for Depression in Adults
- nlmcatalog_books[sb] (7638)NLM Catalog
- hemH [Pseudomonas putida KT2440]hemH [Pseudomonas putida KT2440]Gene ID:1044580Gene
- RAB40AL RAB40A like [Homo sapiens]RAB40AL RAB40A like [Homo sapiens]Gene ID:282808Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...